{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:14:13Z","timestamp":1784006053595,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010816","name":"Anhui Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["202204295107020011"],"award-info":[{"award-number":["202204295107020011"]}],"id":[{"id":"10.13039\/501100010816","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.tranon.2025.102322","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:19:16Z","timestamp":1740140356000},"page":"102322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Individualized tumor-reactive T cells exhibit a potent anti-tumor response in prostate cancer"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3966-3393","authenticated-orcid":false,"given":"Lianjun","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanlin","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houbao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7089-6880","authenticated-orcid":false,"given":"Zhenyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10305","key":"10.1016\/j.tranon.2025.102322_bib0001","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.tranon.2025.102322_bib0002","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/pros.23496","article-title":"National trends in management of localized prostate cancer: a population based analysis 2004-2013","volume":"78","author":"Chen","year":"2018","journal-title":"Prostate"},{"issue":"11","key":"10.1016\/j.tranon.2025.102322_bib0003","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3390\/medicina58111624","article-title":"Micro-ultrasound in the diagnosis and staging of prostate and bladder cancer: a comprehensive review","volume":"58","author":"Calace","year":"2022","journal-title":"Medicina (Kaunas)."},{"issue":"9","key":"10.1016\/j.tranon.2025.102322_bib0004","doi-asserted-by":"crossref","first-page":"FSO745","DOI":"10.2144\/fsoa-2021-0051","article-title":"Fascin-1 and its role as a serological marker in prostate cancer: a prospective case-control study","volume":"7","author":"T\u0103taru","year":"2021","journal-title":"Future Sci. OA"},{"issue":"1","key":"10.1016\/j.tranon.2025.102322_bib0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tranon.2025.102322_bib0006","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2022.01.015","article-title":"Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer","volume":"530","author":"Kang","year":"2022","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.tranon.2025.102322_bib0007","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.3390\/curroncol30060432","article-title":"Immunotherapy in prostate cancer: state of art and new therapeutic perspectives","volume":"30","author":"Maselli","year":"2023","journal-title":"Curr Oncol"},{"issue":"5\u20136","key":"10.1016\/j.tranon.2025.102322_bib0008","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.seminoncol.2018.10.001","article-title":"Current therapeutic options in metastatic castration-resistant prostate cancer","volume":"45","author":"Ingrosso","year":"2018","journal-title":"Semin. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2025.102322_bib0009","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/CCO.0000000000000624","article-title":"Recent progress in treating advanced prostate cancer","volume":"32","author":"Gourdin","year":"2020","journal-title":"Curr. Opin. Oncol."},{"issue":"224","key":"10.1016\/j.tranon.2025.102322_bib0010","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"9967","key":"10.1016\/j.tranon.2025.102322_bib0011","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.tranon.2025.102322_bib0012","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting tgf\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"issue":"399","key":"10.1016\/j.tranon.2025.102322_bib0013","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.tranon.2025.102322_bib0014","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","article-title":"Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients","volume":"147","author":"Zhang","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.tranon.2025.102322_bib0015","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2025.102322_bib0016","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"Sterner RM. CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2025.102322_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.925985","article-title":"CAR T-cell-based gene therapy for cancers: new perspectives, challenges, and clinical developments","volume":"13","author":"Jogalekar","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102322_bib0018","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem. Cell. Res. Ther"},{"issue":"2","key":"10.1016\/j.tranon.2025.102322_bib0019","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI128267","article-title":"Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses","volume":"130","author":"Huang","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.tranon.2025.102322_bib0020","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/carcin\/bgu108","article-title":"Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment","volume":"35","author":"Herrmann","year":"2014","journal-title":"Carcinogenesis"},{"issue":"1\u20132","key":"10.1016\/j.tranon.2025.102322_bib0021","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mce.2003.10.073","article-title":"Immortalization by large T-antigen of the adult epididymal duct epithelium","volume":"216","author":"Kirchhoff","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102322_bib0022","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jcmgh.2018.09.008","article-title":"An organoid-based preclinical model of Human gastric cancer","volume":"7","author":"Steele","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.tranon.2025.102322_bib0023","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nprot.2016.174","article-title":"Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens","volume":"12","author":"Liu","year":"2017","journal-title":"Nat. Protoc."},{"issue":"12","key":"10.1016\/j.tranon.2025.102322_bib0024","doi-asserted-by":"crossref","first-page":"e28732","DOI":"10.1371\/journal.pone.0028732","article-title":"Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses","volume":"6","author":"Chiang","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.tranon.2025.102322_bib0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10120-006-0378-3","article-title":"Assessment of lymph node micrometastasis in early gastric cancer in relation to sentinel nodes","volume":"9","author":"Miyake","year":"2006","journal-title":"Gastric Cancer"},{"issue":"6","key":"10.1016\/j.tranon.2025.102322_bib0026","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of tumor-reactive T cells by Co-culture of peripheral blood lymphocytes and tumor organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"issue":"7738","key":"10.1016\/j.tranon.2025.102322_bib0027","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.tranon.2025.102322_bib0028","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00262-018-2287-9","article-title":"Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad. p53-DC) in patients with recurrent small cell lung cancer","volume":"68","author":"Chiappori","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.tranon.2025.102322_bib0029","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.R120.002309","article-title":"The peptide vaccine of the future","volume":"20","author":"Nelde","year":"2021","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.tranon.2025.102322_bib0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejca.2022.03.015","article-title":"Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: a phase I study","volume":"169","author":"Lau","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2025.102322_bib0031","doi-asserted-by":"crossref","first-page":"E150","DOI":"10.25011\/cim.v31i3.3472","article-title":"Potentiation of the immunotherapeutic effect of autologous dendritic cells by pretreating hepatocellular carcinoma with low-dose radiation","volume":"31","author":"Lin","year":"2008","journal-title":"Clin. Invest. Med."},{"issue":"6","key":"10.1016\/j.tranon.2025.102322_bib0032","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of tumor-reactive T cells by Co-culture of peripheral blood lymphocytes and tumor organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325000531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325000531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:34:41Z","timestamp":1762562081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523325000531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":32,"alternative-id":["S1936523325000531"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102322","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualized tumor-reactive T cells exhibit a potent anti-tumor response in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102322"}}